New results from two randomized trials show cryoablation with Medtronic plc’s cryoablation technology provides a better primary option for treatment of recurrent symptomatic paroxysmal atrial fibrillation than antiarrhythmic drugs.
Paroxysmal atrial fibrillation frequently progresses to chronic atrial fibrillation, increasing the patient’s risk of heart failure hospitalization and mortality while also reducing their quality of life. The current standard...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?